GIBSON DUNN

Gibson Dunn Advises Jade Biosciences on $135 Million Private Placement

Firm News | October 15, 2025

Gibson Dunn represented Jade Biosciences, Inc. in connection with a private placement of securities generating aggregate gross proceeds of approximately $135 million to both new and existing investors including Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace, Aberdeen Investments, Great Point Partners, LLC, Venrock Healthcare Capital Partners, Samsara BioCapital, Avidity Partners, and several other leading healthcare investors.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade is based in Massachusetts.

Gibson Dunn regularly advises life sciences companies and healthcare investors on private placements and capital markets transactions in the biotechnology sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Nick Linke, Candice Johnson, Jasmine Vitug, and Lauren Guzman.

Related Capabilities

Capital Markets

Mergers and Acquisitions

Life Sciences

Private Equity

Related People

Ryan A. Murr

Branden C. Berns

Nicholas G. Linke

Candice D. Johnson

Jasmine L. Vitug

Lauren Guzman

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**